Tirzepatide — Indexed Studies

Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?

Azeem S, Bulushi LA, Sabt BI

Tirzepatide and metformin effects on hunger and BMI in an adolescent with hyperphagia and severe obesity due to MC4R Deficiency: a case report.

van der Walle EEPL, Boon MR, van Rossum EFC et al.

Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity.

Takizawa H, Tsuda A, Suriki H et al.

Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A critical appraisal.

Corrao S

Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.

Violante-Ortiz R, Rose L, Sharma P et al.

Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.

Boye KS, Sharma P, Chivukula KK et al.

GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.

Musa EYA, Musa AYA

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

Nissen SE, Wolski K, D'Alessio D et al.

Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.

Barenbaum SR, Gonzalez A, Verzani Z et al.

The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.

Sillassen CDB, Faltermeier P, Bjerg JL et al.

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.

Galindo RJ, Gudzune KA, Look M et al.

Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.

Soliman A, Hamour B, Hammad A et al.

Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.

Mazzeo A, Alaimo V, Grimaldi LM

Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.

Yang SI, Kim SW, Son KH et al.

Forword for efficacy and safety of tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Leikin JB

Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Sebastian SA, Ayyalu T, Bimal T et al.

Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.

Mortada I, Lee A, Quach V et al.

Euglycemic diabetic ketoacidosis following treatment with tirzepatide and SGLT-2 inhibitors: A case report and literature review.

Sawamura T, Karashima S, Ohmori A et al.

Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report.

Minoda Y, Ikeda S, Inukai K et al.

ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.

Zheng Z, Pettus JH, Warner A et al.

Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.

Ciudin A, Sapin H, Fan L et al.

Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.

Mondoh A, Contreras F, Craig H et al.

Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.

Gougol A, Kwo P, Pike W et al.

Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.

Akturk HK, Mason E, Cengiz D et al.

Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.

Akturk HK, Karakus KE, Cengiz D et al.

Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.

Iglesias P, Nobre EL, Hanzu F et al.

Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?

Chen M, Han Y, Zhang F

Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.

Seminara G, Leuzzi M, Meduri L et al.

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks.

Heerspink HJL, van Raalte DH, Tuttle K et al.

Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.

Shinde S, Kanu C, Varnado OJ et al.

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

Kanumilli N, Osumili B, Evans J et al.

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.

Shokravi A, Seth J, Mancini GBJ

Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.

Wells DA, Duncan K, Sakaan S

Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.

Campana C, Heaney A, Ceraolo N et al.

Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.

Wong M, Wu A, Garhe PK et al.

Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.

Schmickl CN, Tripipitsiriwat A, Mokhlesi B et al.

Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.

Almukhadeb E, Nagshabandi KN, Alshehri N et al.

Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.

Wu Y, Wang Z, Tuersun A et al.

Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.

Monzo L, Savarese G, Duarte K et al.

Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.

Sekhon S, Kahlon I, Latson W

Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.

Menkü Özdemir FD, Uzun H

Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.

Minakata Y, Miura M, Nakatake N et al.

Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.

Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures.

Liu Y, Walzer D, Schmitz S et al.

Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.

Jain V, McMullen CA, Kimbrough JI et al.

A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.

le Roux CW, Busetto L, Aronne L et al.

Improvement of Compulsive Shopping on Tirzepatide: A Case Report.

Guerdjikova AI, Walter LL, McElroy SL

Drug-induced liver injury secondary to tirzepatide.

Cao CY, Subhaharan D, Mikhail-Gouda P et al.

Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.

Benny O, Agarwal A, Alecock H et al.

Correction: Weight loss efficiency and safety of tirzepatide: A Systematic review.

Lin F, Yu B, Ling B et al.